COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Chow47%0.53 [0.31-0.90]death26/9873/314Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Tau​2​ = 0.15; I​2​ = 78.6%Late treatment33%0.67 [0.44-1.02]1,261/7,8271,389/8,41433% improvementYuan4%0.96 [0.47-1.72]death11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Tau​2​ = 0.31; I​2​ = 85.9%PrEP41%0.59 [0.26-1.35]283/6,352690/6,43141% improvementAll studies37%0.63 [0.40-0.99]1,544/14,1792,079/14,84537% improvement7 aspirin COVID-19 studiesc19aspirin.com Aug 29, 2021Tau​2​ = 0.29; I​2​ = 95.4%; Z = 1.99Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]2/2811/204Chow47%0.53 [0.31-0.90]26/9873/314Horby (RCT)4%0.96 [0.89-1.04]1,222/7,3511,299/7,541Tau​2​ = 0.17; I​2​ = 83.9%Late treatment39%0.61 [0.38-0.99]1,250/7,7961,383/8,37839% improvementYuan4%0.96 [0.47-1.72]11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]272/6,300661/6,300Tau​2​ = 0.31; I​2​ = 85.9%PrEP41%0.59 [0.26-1.35]283/6,352690/6,43141% improvementAll studies41%0.59 [0.36-0.96]1,533/14,1482,073/14,80941% improvement6 aspirin COVID-19 mortality resultsc19aspirin.com Aug 29, 2021Tau​2​ = 0.30; I​2​ = 96.1%; Z = 2.13Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Chow43%0.57 [0.38-0.85]38/98160/314Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment43%0.57 [0.38-0.85]38/98160/31443% improvementAll studies43%0.57 [0.43-0.75]38/98160/31443% improvement1 aspirin COVID-19 ICU resultc19aspirin.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 4.06Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Chow47%0.53 [0.31-0.90]death26/9873/314Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Tau​2​ = 0.15; I​2​ = 78.6%Late treatment33%0.67 [0.44-1.02]1,261/7,8271,389/8,41433% improvementYuan4%0.96 [0.47-1.72]death11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Tau​2​ = 0.31; I​2​ = 85.9%PrEP41%0.59 [0.26-1.35]283/6,352690/6,43141% improvementAll studies37%0.63 [0.40-0.99]1,544/14,1792,079/14,84537% improvement7 aspirin COVID-19 serious outcomesc19aspirin.com Aug 29, 2021Tau​2​ = 0.29; I​2​ = 95.4%; Z = 1.99Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Liu (PSM)-2%1.02 [0.64-1.61]24 (n)24 (n)Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment-2%1.02 [0.64-1.61]0/240/24-2% improvementAll studies-2%1.02 [0.64-1.61]0/240/24-2% improvement1 aspirin COVID-19 viral clearance resultc19aspirin.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 0.08Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment4%0.96 [0.89-1.04]1,222/7,3511,299/7,5414% improvementAll studies4%0.96 [0.89-1.03]1,222/7,3511,299/7,5414% improvement1 aspirin COVID-19 Randomized Controlled Trialsc19aspirin.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.12Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Horby (RCT)4%0.96 [0.89-1.04]1,222/7,3511,299/7,541Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment4%0.96 [0.89-1.04]1,222/7,3511,299/7,5414% improvementAll studies4%0.96 [0.89-1.03]1,222/7,3511,299/7,5414% improvement1 aspirin COVID-19 RCT mortality resultc19aspirin.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.12Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Chow47%0.53 [0.31-0.90]death26/9873/314Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Tau​2​ = 0.02; I​2​ = 14.5%Late treatment45%0.55 [0.41-0.76]39/47690/87345% improvementYuan4%0.96 [0.47-1.72]death11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Tau​2​ = 0.31; I​2​ = 85.9%PrEP41%0.59 [0.26-1.35]283/6,352690/6,43141% improvementAll studies45%0.55 [0.40-0.75]322/6,828780/7,30445% improvement6 aspirin COVID-19 peer reviewed trialsc19aspirin.com Aug 29, 2021Tau​2​ = 0.08; I​2​ = 62.9%; Z = 3.72Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Liu (PSM)81%0.19 [0.05-0.78]death1/289/204Liu (PSM)-2%1.02 [0.64-1.61]viral time24 (n)24 (n)Chow47%0.53 [0.31-0.90]death26/9873/314Chow44%0.56 [0.37-0.85]ventilation35/98152/314Chow43%0.57 [0.38-0.85]ICU38/98160/314Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Horby (RCT)17%0.83 [0.66-1.04]death129/466169/513Horby (RCT)7%0.93 [0.82-1.05]death1,222/7,3511,299/7,541Horby (RCT)5%0.95 [0.87-1.05]ventilation772/6,993829/7,169Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Yuan4%0.96 [0.47-1.72]death11/5229/131Osborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Osborne (PSM)60%0.40 [0.33-0.48]death170/6,814427/6,814aspirin COVID-19 outcomesc19aspirin.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home